Effects of α-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer in vitro

World Journal of Gastroenterology

Volumn 14, Issue 15, 2008, Pages 2358-2363

  Shen, Su Gang ^a   Zhang, Dong ^a   Hu, Heng Tong ^a   Li, Jun Hui ^a   Wang, Zheng ^a   Ma, Qing Yong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Alpha adrenoreceptor; Pancreatic cancer; Urapidil hydrochloride; Yohimbine

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOTIN; BROMINE DERIVATIVE; MESSENGER RNA; TETRAZOLIUM; URAPIDIL; YOHIMBINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; PANCREAS ADENOCARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 45849103828     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2358     Document Type: Article

References (26)

1. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58: 231-241
2. Michalski CW, Weitz J, Buchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 2007; 4: 526-535
3. Verslype C, Van Cutsern E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordljnger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007; 18 Suppl 7: vii1-vii10
4. Ghaneh P, Slavin J, Sutton R, Hartley M, Neoptolemos JP. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2001; 7: 482-489
5. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209
6. Del Chiaro M, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N, Boggi U, Casari G, Longoni BM, Salvia R, Caligo MA, Di Carlo V, Pederzoli P, Presciuttini S, Mosca F. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 2007; 7: 459-469
7. Weddle DL, Tithoff P, Williams M, Schuller HM. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001; 22: 473-479
8. Schuller HM, Tithof PK, Williams M, Plummer H 3rd. The tobacco- specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 1999; 59: 4510-4515
9. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 1996; 33: 255-260
10. Odore R, Bactino P, Stammati AL, De Angelis I, Zucco F, Belloli C, Re G. Identification of functional beta-adrenoceptors in Caco-2 cell membranes. Vet Res Commun 2003; 27 Suppl 1: 415-418
11. Nagmani R, Pasco DS, Salas RD, Feller DR. Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. Biochem Pharmacol 2003; 65: 1489-1494
12. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002; 2: 455-463
13. Lutz H, Brian K, Kobilka. Adrenergic Receptors From Molecular Structure to in vivo Function. Trends Cardiovasc Med 1997; 7: 137-145
14. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res 2001; 44: 195-208
15. Wallukat G. The beta-adrenergic receptors. Herz 2002; 27: 683-690
16. Summers RJ, Kompa A, Roberts SJ. Beta-adrenoceptor subtypes and their desensitization mechanisms. J Auton Pharmacol 1997; 17: 331-343
17. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess 0, Indolfi C, Rimoldi 0. alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000; 101: 689-694
18. Vazquez SM, Mladovan AG, Perez C, Bruzzone A, Baldi A, Luthy IA. Human breast cell lines exhibit functional alpha2-adrenoceptors. Cancer Chemother Pharmacol 2006; 58: 50-61
19. Vazquez SM, Pignataro O, Luthy IA. Alpha2-adrenergic effect on human breast cancer MCF-7 cells. Breast Cancer Res Treat 1999; 55: 41-49
20. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol 1998; 361: 1-15
21. Davey M. Mechanism of alpha blockade for blood pressure control. Am J Cardiol 1987; 59: 18G-28G
22. McGrath JC, Naghadeh MA, Pediani JD, Mackenzie JF, Daly CJ. Importance of agonists in alpha-adrenoceptor classification and localisation of alphal-adrenoceptors in human prostate. Eur Urol 1999; 36 Suppl. 1: 80-88
23. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169: 1520-1525
24. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60: 4550-4555
25. Alblas J, van Corven EJ, Hordijk PL, Milligan G, Moolenaar WH. Gi-mediated activation of the p21ras-n-dtogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. J Biol Chem 1993; 268: 22235-22238
26. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005; 31: 301-316